# GLP-1 Non Responders: New Gene Study and What It Means

Source: https://www.dietglp.com/blog/glp-1-non-responders/
Published: 2026-11-13
Keywords: glp-1 non responders, glp 1 non responders, what is a glp 1 non responder, non responders to glp 1, glp 1 agonist non responders, glp 1 slow responder, glp 1 super responders, glp 1 genetic testing, glp 1 dna test, glp 1 genetic studies, why ozempic doesn't work for some people, why is ozempic not working for me, what if ozempic doesn't work, ozempic and genetics, why is glp-1 not working for me

**TL;DR:** GLP-1 non responders are people who lose little or no weight on drugs like Wegovy, Ozempic or Zepbound. In the big trials, about 1 in 7 people lost less than 5% of their body weight. A study published November 11, 2026 in Nature Metabolism found one cause: rare changes in the GLP1R gene. Carriers lost 2.4% of their weight on semaglutide vs 8.8% for similar people without the change, but they did nearly as well as everyone else on tirzepatide. Only about 1 in 400 treated people carried one, so genes explain a small share of slow results. Whatever your pace, [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) helps make sure the weight you lose is fat, not muscle, with one protein target, one 20-minute workout and one Shape Score a day.

Some people take a GLP-1 for months and barely lose weight. They are often called GLP-1 non responders, and until now nobody could say why it happens. A study published on November 11, 2026 in Nature Metabolism gives one clear answer for a small group: rare changes in the GLP1R gene, which builds the receptor these drugs act on. Carriers lost about one quarter of the usual weight on semaglutide (Wegovy, Ozempic). On tirzepatide (Zepbound, Mounjaro) they lost nearly as much as everyone else.

Here is what the study found, how many people it applies to, and what else can slow your results.

## What is a GLP-1 non responder?

There is no official definition. The big trials count a "responder" as someone who loses at least 5% of their starting weight. By that measure, most people respond, but not all.

| Trial | Drug and dose | Length | Lost 5% or more | Did not |
|---|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg | 68 weeks | 86.4% | about 14% |
| SURMOUNT-1 | Tirzepatide 5 mg | 72 weeks | 85% | about 15% |
| SURMOUNT-1 | Tirzepatide 10 mg | 72 weeks | 89% | about 11% |
| SURMOUNT-1 | Tirzepatide 15 mg | 72 weeks | 91% | about 9% |

These counts include people who stopped the drug early, so not every "non responder" stayed on treatment. Still, roughly 1 in 7 to 1 in 10 people fell short of 5%. You may also see "slow responder" for people who get there late, and "super responder" for people who lose far more than average. None of these are medical diagnoses.

## The new gene study: what it found

The paper is called "Rare GLP1R variants attenuate weight loss with semaglutide but not tirzepatide." The lead author is Matthew Levy of Helix, a genetics company. The team used the Helix Research Network, which links gene sequencing to health records for 351,818 people at 13 North American health systems.

They looked at 13,725 adults with a BMI of 25 or higher who started injectable semaglutide or tirzepatide in normal care. Then they found the people with a rare, likely damaging variant in GLP1R and matched each one to up to 10 similar people without it. The match used drug, dose, sex, diabetes status, starting BMI and time on treatment. Weight change was measured after 6 to 12 months.

| Group | Carriers lost | Matched non-carriers lost | Carriers got |
|---|---|---|---|
| Semaglutide (17 carriers) | 2.4% | 8.8% | 27% of the usual loss |
| Tirzepatide (19 carriers) | 13.3% | 15.2% | 88% of the usual loss |
| Both drugs together (33 carriers) | 8.2% | 12.5% | 65% of the usual loss |

The semaglutide gap was statistically significant. The tirzepatide gap was not. Of the 17 carriers on semaglutide, 15 lost less than their matched group. The gap held at higher semaglutide doses (1.7 mg and up) too.

## Why would tirzepatide still work?

Semaglutide acts on one target, the GLP-1 receptor. If that receptor works poorly, the drug has less to push on. Tirzepatide acts on two targets, the GLP-1 receptor and the GIP receptor. The authors think the second target may make up for a weak first one. They call this idea speculative and say lab work is needed to prove it.

They also checked rare variants in the GIP receptor gene (GIPR). Those did not clearly change results on either drug. Our [semaglutide vs tirzepatide guide](/blog/semaglutide-vs-tirzepatide/) explains how the two drugs differ in more detail.

## How common are these GLP1R variants?

Rare. Only 33 of the 13,725 treated people carried one. That is about 0.2%, or roughly 1 in 400. So this finding explains a small slice of GLP-1 non responders. If your results are slow, a rare GLP1R variant is possible but unlikely to be the reason.

Common variants matter a little too:

- **P7L (rs10305420).** About 36% of gene copies in the study were this version. Each copy was tied to about 5% more weight loss. This matches an April 2026 study in Nature of 27,885 people, which found about 0.76 kg of extra loss per copy.
- **Ala316Thr (rs10305492).** A less common version, tied to about 13% less weight loss per copy.

These are small nudges next to the rare variants, whose effect was about 12 times larger.

## Is there GLP-1 genetic testing I can get?

Not as a standard step. No label for Wegovy, Ozempic, Zepbound or Mounjaro asks for a gene test before you start. The study used research-grade sequencing done inside health systems. It did not test whether choosing a drug by gene result gives people better outcomes. That would take a new trial.

Keep the limits in mind as well:

- The carrier groups were small: 17 and 19 people.
- It used real-world records, where missed doses and weigh-ins are not tracked perfectly.
- Most carriers had European ancestry.
- Eight of the authors work for Helix, the genetics company behind the network.
- A check in the separate All of Us database pointed the same way (8 carriers, 2.6% vs 5.7% lost) but was too small to be statistically significant. A second Helix group of new patients did confirm it (7 carriers, 4.1% vs 7.5%).

The authors say carriers may be better suited to tirzepatide. That is a research suggestion, not a treatment rule.

## Why is my GLP-1 not working? Other reasons

Genes are one piece. These are more common, and each is worth raising with your prescriber:

- **Type 2 diabetes.** People with diabetes tend to lose less. In STEP 2, semaglutide 2.4 mg led to 9.6% weight loss in adults with type 2 diabetes, vs 14.9% in STEP 1 without it.
- **Missed or stretched doses.** A CDC report this week found 28% of users skip doses. See our [missed GLP-1 dose guide](/blog/missed-glp-1-dose/).
- **Not at a full dose yet.** The labels start low and step up over months. Early weeks are not a fair test.
- **A plateau, not a non-response.** If you lost weight and then stalled, that is a different problem. Our [GLP-1 plateau guide](/blog/plateau-on-glp1/) covers it.

A slow scale can also hide a good change. If you lift and eat enough protein, you can lose fat while holding muscle, and the scale moves less than your waist does. This is where [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) helps: it gives you one protein target and one 20-minute workout a day, and its Shape Score tracks your body shape, not just your weight.

## What to do if you think you are a non responder

1. **Log it.** Write down your weight weekly, your dose, and any missed doses. Add a waist measurement.
2. **Give it the time the label gives it.** Dose steps take months.
3. **Bring the log to your prescriber.** Ask what a fair trial looks like for you and what the options are if you fall short.
4. **Do not change the drug yourself.** Do not raise, split, stop or swap a dose on your own, and do not turn to compounded or research versions.
5. **Protect your muscle either way.** Slow loss or fast loss, protein and strength work decide what the weight is made of. Our [Ozempic muscle loss guide](/blog/ozempic-muscle-loss/) shows how.

## The bottom line

Most people respond to GLP-1 drugs, but about 1 in 7 to 1 in 10 lose less than 5% in trials. The new Nature Metabolism study shows that rare GLP1R gene variants can cut semaglutide weight loss to about a quarter of normal while leaving tirzepatide mostly intact. It applies to roughly 1 in 400 people, the groups were small, and no label calls for gene testing. If your results are slow, bring a clear log to your prescriber. And keep your protein and strength work steady with [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138), so the weight you do lose is fat.

## Sources

- [Levy et al., Nature Metabolism, November 11, 2026: Rare GLP1R variants attenuate weight loss with semaglutide but not tirzepatide](https://www.nature.com/articles/s42255-026-01656-z)
- [Su et al., Nature, April 8, 2026: Genetic predictors of GLP1 receptor agonist weight loss and side effects](https://www.nature.com/articles/s41586-026-10330-z)
- [Wilding et al., NEJM 2021: STEP 1, semaglutide 2.4 mg in adults with overweight or obesity](https://pubmed.ncbi.nlm.nih.gov/33567185/)
- [Jastreboff et al., NEJM 2022: SURMOUNT-1, tirzepatide for obesity](https://pubmed.ncbi.nlm.nih.gov/35658024/)
- [Davies et al., Lancet 2021: STEP 2, semaglutide 2.4 mg in adults with type 2 diabetes](https://pubmed.ncbi.nlm.nih.gov/33667417/)


## Frequently asked questions

**Q: What is a GLP-1 non responder?**

A: There is no official definition. Trials count a "responder" as someone who loses 5% or more of their body weight, so a non responder is usually someone who loses less than that on a full dose. In STEP 1, 86.4% of people on semaglutide 2.4 mg reached 5%, which means about 14% did not.

**Q: Why does Ozempic not work for some people?**

A: Several things can blunt the result: type 2 diabetes, missed doses, not reaching a full dose, and other health issues. A November 2026 study in Nature Metabolism adds a genetic cause. People with rare damaging variants in the GLP1R gene lost about one quarter of the usual weight on semaglutide. That gene finding applies to roughly 0.2% of treated people.

**Q: Is there GLP-1 genetic testing to predict weight loss?**

A: No GLP-1 label asks for a gene test before you start. The new study used research-grade exome sequencing inside health systems. It did not test whether picking a drug by gene result leads to better outcomes. If you are curious, ask your prescriber rather than buying a test on your own.

**Q: Do GLP-1 non responders do better on tirzepatide?**

A: In this one study, carriers of rare GLP1R variants lost 13.3% of their body weight on tirzepatide vs 15.2% for matched non-carriers, a gap that was not statistically significant. The numbers are small, 19 carriers, so it is a signal and not proof. Any switch is a decision for you and your prescriber.

**Q: What are GLP-1 super responders?**

A: It is an informal name for people who lose far more than average. An April 2026 study in Nature of 27,885 people linked a common GLP1R variant to about 0.76 kg of extra weight loss per copy. The new study saw the same pattern, about 5% more weight loss per copy. That is a small boost, not a guarantee.

**Q: How long should I wait before deciding a GLP-1 is not working?**

A: The labels start low and raise the dose over months, so early weeks are not a fair test. The new study measured weight change after 6 to 12 months of treatment. Bring your weight log to your prescriber and decide together. Do not raise, stop or swap a dose on your own.

